Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From Adult to Adolescent: Alignment in Clinical Trials and Outcomes in Axial Spondyloarthritis.

Arthritis care & research·2026
Same author

Interdisciplinary Clinical Practice Guidelines for patient-centred management of juvenile-onset systemic lupus erythematosus.

EULAR rheumatology open·2026
Same author

Differences in time to drug initiation and inactive disease achievement by insurance type in patients with nonsystemic juvenile idiopathic arthritis.

Drugs & therapy perspectives : for rational drug selection and use·2026
Same author

Impact of tofacitinib on growth in patients with juvenile idiopathic arthritis.

Annals of the rheumatic diseases·2026
Same author

Effective Performance of the 2022 American College of Rheumatology/EULAR Classification Criteria for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in Pediatric Patients: An ARChiVe Study.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

CAR T-cell therapy and indications for pediatric rheumatology: Structured overview of applications, risks, and considerations.

Best practice & research. Clinical rheumatology·2026

Related Experiment Video

Updated: Jun 3, 2026

Clinical Efficacy of an Innovative Multidimensional Traction Therapy in Moderate Adolescent Idiopathic Scoliosis
07:12

Clinical Efficacy of an Innovative Multidimensional Traction Therapy in Moderate Adolescent Idiopathic Scoliosis

Published on: February 10, 2026

Pediatric SLE--towards a comprehensive management plan.

Hermine I Brunner1, Jennifer Huggins, Marisa S Klein-Gitelman

  • 1William S. Rowe Division of Rheumatology & Lupus Center, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, Cincinnati, OH 45229-3039, USA. hermine.brunner@cchmc.org

Nature Reviews. Rheumatology
|March 10, 2011
PubMed
Summary
This summary is machine-generated.

Childhood-onset systemic lupus erythematosus (SLE) presents unique challenges, often with more severe disease and requiring aggressive treatment. Comprehensive, multidisciplinary care is essential for managing pediatric patients with SLE.

More Related Videos

Robot-Assisted Laparoscopic Splenectomy In Children: A Case Report with Literature Review
05:06

Robot-Assisted Laparoscopic Splenectomy In Children: A Case Report with Literature Review

Published on: March 27, 2026

Related Experiment Videos

Last Updated: Jun 3, 2026

Clinical Efficacy of an Innovative Multidimensional Traction Therapy in Moderate Adolescent Idiopathic Scoliosis
07:12

Clinical Efficacy of an Innovative Multidimensional Traction Therapy in Moderate Adolescent Idiopathic Scoliosis

Published on: February 10, 2026

Robot-Assisted Laparoscopic Splenectomy In Children: A Case Report with Literature Review
05:06

Robot-Assisted Laparoscopic Splenectomy In Children: A Case Report with Literature Review

Published on: March 27, 2026

Area of Science:

  • Immunology
  • Pediatrics
  • Rheumatology

Background:

  • Systemic lupus erythematosus (SLE) involves complex immune system dysregulation.
  • Childhood-onset SLE typically exhibits a more severe disease course and phenotype compared to adult-onset SLE.
  • Factors contributing to disease severity in pediatric SLE remain incompletely understood.

Purpose of the Study:

  • To highlight the distinct characteristics and challenges of childhood-onset SLE.
  • To emphasize the need for specialized management strategies in pediatric lupus patients.
  • To underscore the importance of a multidisciplinary approach for optimal patient outcomes.

Main Methods:

  • This abstract is based on a review of current understanding of childhood-onset SLE.
  • It synthesizes information on disease presentation, treatment, and management considerations.
  • No specific experimental methods were detailed in the provided abstract.

Main Results:

  • Childhood-onset SLE is associated with higher morbidity and mortality, particularly with active disease, infections, lupus nephritis, and neuropsychiatric manifestations.
  • The majority of pediatric SLE patients require systemic glucocorticoid and immunosuppressive therapy.
  • Disease course and complications are variable and unpredictable.

Conclusions:

  • Childhood-onset SLE necessitates a comprehensive, multidisciplinary management plan.
  • Management must address patients' growth, development, and educational needs alongside SLE complications.
  • Aggressive treatment strategies are often required for pediatric SLE patients.